It has been announced, that a novel application of 3D-Bioprinting living tissue models for pharmaceutical testing is being developed at Swansea University-UK. A team of scientists have begun trailing a process, which has been designed to augment the development of new drugs and treatments. The research team led by Dr. Daniel Thomas of the Welsh Centre for Printing and Coating has produced a process which uses precision deposition technologies to produce complex tissue architectures.
Over the past decade, annual spending on pharmaceutical development has doubled to more than £30 billion per annum. At the same time, in spite of these huge sums invested, the average number of drugs being approved for human use has decreased to one in ten. Currently, pre-clinical studies to test the safety and efficiency of new drugs use laboratory animals and traditional 2D cell culture models. Neither of these methods are completely accurate reflections of how a drug will react in a human.
A solution has emerged in the form of 3D-Bioprinting technology developed for the scalable, accurate and repeatable deposition of biologically active materials. With advances in this bio-manufacturing technology, durable biological tissues for use in testing new pharmaceutical products are now being harnessed and refined.
Dr. Thomas explains “Using self-differentiation 3D bioprinting processes, then it is not necessary to print all of the details required to form a tissue. The concept is that once the relevant cells are placed in the right place, nature completes the process. This is as such a top down method for engineering new ways towards making tissue structures, which is no different to cells in an embryo knowing how to configure themselves into complicated organs. Nature has been evolving this capability for four billion years, and we can use this process to our advantage. Thus we do not have to print networks of vasculature and innervated layers using this approach, as these can be produced by using specific three dimensional stem cell differentiation processes.”
Going forward, 3D Bioprinting is being explored as a method for the creation of more advanced structures. In the longer-term, this technology offers the potential to fabricate organised tissue constructs. This is being engineered to repair and/or replace damaged or diseased human tissues, and directly has a bearing for developing safer and more effective healthcare treatments. It also opens up the opportunity for cost effective patient specific tissue engineering to evolve. However, fundamental obstacles include balancing scaffold properties to optimise; resolution, cell migration, proliferation and differentiation need to be overcome, one step at a time.
“By further engineering this process then we can produce tissues which have measurable mechanical, metabolic and functional properties. This is from the perspective of using shaped scaffold bioprinting technology which produces complex structures.” said Dr. Thomas.
This process specifically deposits an Extra Cellular Matrix (ECM) protein scaffold in 3D. ECM is a biochemical support material between all cells and is critical towards the formation of a tissue structure.
The potential to produce functional tissues on demand, made in a controlled and safe way for use in humans could one day revolutionize healthcare. In the future, 3D-Bioprinting technology could have a huge global impact on healthcare and the economy.
You May Also Like
Dream M&As: 3D Printing Mergers and Acquisitions We’d Like to See in 2021, Part 3
Inspired in part by the acquisition of EnvisionTEC by Desktop Metal, of 3D Hubs by ProtoLabs, and of Origin by Stratasys, we’ve been brainstorming about the newly hot 3D printing stocks and renewed interest...
3D Printing News Briefs, January 23, 2021: CADENAS, BCN3D, ExOne & AMGTA, 6K
We’ve got some business news for you in this weekend edition of 3D Printing News Briefs! CADENAS and BCN3D are both reporting good news from 2020, and ExOne has just...
CEO Meddah Hadjar to Leave SLM Solutions
SLM Solutions (AM3D.DE) has announced that its CEO, Meddah Hadjar, will not be extending his contract with the company at the end of January 2021. The company has stated the...
Dream M&As: 3D Printing Mergers and Acquisitions We’d Like to See in 2021, Part 2
Inspired in part by the acquisition of EnvisionTEC by Desktop Metal and of Origin by Stratasys, we’ve been brainstorming about the newly hot 3D printing stocks and renewed interest from investors in our markets. Is 2021 going...
View our broad assortment of in house and third party products.